ENTRADA THERAPEUTICS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross
ENTRADA THERAPEUTICS, INC. (TRDA) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross of 883.60 thousand shares for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Shareholders' Equity › Share-Based Compensation Arrangement by Share-Based Payment Award, Options, Grants in Period, Net of Forfeitures
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross · last filed 2026-08-05
- ENTRADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-06-30 was 114.00K shares, a 14.29% decline year-over-year.
- ENTRADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2026-03-31 was 769.60K shares, a 10.57% increase year-over-year.
- ENTRADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-12-31 was 38.85K shares, a 100.00% increase year-over-year.
- ENTRADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for the quarter ending 2025-09-30 was 38.85K shares, a 100.00% increase year-over-year.
- ENTRADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2025 was 906.75K shares, a 29.71% increase from fiscal 2024.
- ENTRADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2024 was 699.05K shares, a 12.53% decline from fiscal 2023.
- ENTRADA THERAPEUTICS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, gross for fiscal 2023 was 799.14K shares.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross 12 month |
|---|---|---|---|---|
| 2026-06-30 | 114.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | 883.60K shares 10-Q · filed 2026-08-05 | 922.45K shares derived: sum of 3 quarters · filed 2026-08-05 | 961.30K shares derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | 769.60K shares 10-Q · filed 2026-05-07 | 808.45K shares derived: sum of 2 quarters · filed 2026-05-07 | 847.30K shares derived: sum of 3 quarters · filed 2026-05-07 | 980.30K shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 38.85K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 77.70K shares derived: sum of 2 quarters · filed 2026-02-26 | 210.70K shares derived: sum of 3 quarters · filed 2026-02-26 | 906.75K shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 38.85K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 171.85K shares derived: sum of 2 quarters · filed 2025-11-06 | 867.90K shares 10-Q · filed 2025-11-06 | 887.33K shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 133.00K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | 829.05K shares 10-Q · filed 2025-08-06 | 848.48K shares derived: sum of 3 quarters · filed 2025-08-06 | 867.90K shares derived: sum of 4 quarters · filed 2025-08-06 |
| 2025-03-31 | 696.05K shares 10-Q · filed 2025-05-08 | 715.48K shares derived: sum of 2 quarters · filed 2025-05-08 | 734.90K shares derived: sum of 3 quarters · filed 2025-05-08 | 852.40K shares derived: sum of 4 quarters · filed 2025-05-08 |
| 2024-12-31 | 19.43K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 38.85K shares derived: sum of 2 quarters · filed 2025-02-27 | 156.35K shares derived: sum of 3 quarters · filed 2025-02-27 | 699.05K shares 10-K · filed 2025-02-27 |
| 2024-09-30 | 19.43K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-05 | 136.93K shares derived: sum of 2 quarters · filed 2024-11-05 | 679.63K shares 10-Q · filed 2024-11-05 | 679.63K shares derived: sum of 4 quarters · filed 2024-11-05 |
| 2024-06-30 | 117.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | 660.20K shares 10-Q · filed 2024-08-13 | 660.20K shares derived: sum of 3 quarters · filed 2024-08-13 | 981.65K shares derived: sum of 4 quarters · filed 2024-08-13 |
| 2024-03-31 | 542.70K shares 10-Q · filed 2024-05-07 | 542.70K shares derived: sum of 2 quarters · filed 2024-05-07 | 864.15K shares derived: sum of 3 quarters · filed 2024-05-07 | 991.45K shares derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-13 | 321.45K shares derived: sum of 2 quarters · filed 2024-03-13 | 448.75K shares derived: sum of 3 quarters · filed 2024-03-13 | 799.14K shares 10-K · filed 2024-03-13 |
| 2023-09-30 | 321.45K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | 448.75K shares derived: sum of 2 quarters · filed 2023-11-07 | 799.14K shares 10-Q · filed 2023-11-07 | |
| 2023-06-30 | 127.30K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 477.70K shares 10-Q · filed 2023-08-08 | ||
| 2023-03-31 | 350.40K shares 10-Q · filed 2023-05-10 | |||
| 2022-09-30 | 510.46K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-07 | 661.67K shares derived: sum of 2 quarters · filed 2022-11-07 | 1.66M shares 10-Q · filed 2022-11-07 | |
| 2022-06-30 | 151.21K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 1.15M shares 10-Q · filed 2022-08-11 | ||
| 2022-03-31 | 999.32K shares 10-Q · filed 2022-05-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |